Replies to post #1477 on LifeLoc Technologies Inc (LCTC)

[Energy Manager]

The new rule of allowing saliva drug tests by the Department of transportation took effect on June 1, 2023. The DOT specifically mentioned THC and Cocaine in their ruling... “Allowing employers to use oral fluid testing may improve the effectiveness of drug testing,” DOT said. “Oral fluid testing can detect the recent use of some drugs, including marijuana and cocaine, while urine drug testing has a longer window of detection.”

Yes, the DOT finalized rule sets a 4 nanogram per milliliter screening test cutoff for THC, which it said in its earlier notice “would detect use of marijuana while eliminating possibilities of positive tests resulting from passive exposure.” I'm certain that Lifeloc is concentrating their efforts to improve the accuracy of their drug testing platform to meet the criteria set by the DOT.

A very important thing to remember here, is that prior to June 1, there was no set cutoff point for the amount of THC to be considered "over the limit." The DOT has now set this limit, which now creates a set point for testing, much like alcohol is set at .04 for commercial drivers, and .08 for most other drivers in most states. The argument that "there is no predetermined amount of THC in your system to be considered over the limit," is no longer valid. The DOT has set it at 4ng/ml.

For Lifeloc to achieve what they have in their R&D of this new product, without diluting shareholder value, and maintaining profitability, is an amazing feat in itself. Most small, OTC companies have no real revenue streams, and rely on their operations being completely funded by sale of their common stock. This is why there is such aversion from large fund investing in OTC companies. Lifeloc stands out of the crowd here, and, in my opinion, is being largely overlooked by investors. This is why buying now, when there is little to no interest in shares of LCTC stock, makes sense.

The management at Lifeloc seem to be confident in the product, and are starting to comment on the progress they are making - including current validation testing being performed on human samples. Still flying under the radar, but not for long....